Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAnthem CA-125 Testing Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedAnthemPolicy CG-LAB-32

    Cancer Antigen 125 Testing

    Customize your policy alerts

    Sign up for Anthem Policy CG-LAB-32 alerts

    Get alerted when Policy CG-LAB-32 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when quantitative CA-125 tumor-marker testing is medically necessary for evaluating suspected or diagnosed malignancy, assessing residual disease, monitoring treatment response, evaluating recurrence, and selected high-risk surveillance for Anthem commercial members.

    Policy Summary
    PayerAnthem
    PolicyCancer Antigen 125 Testing
    Policy CodePolicy CG-LAB-32
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewAug 13, 2026
    Next Review DateNot specified
    Key ActionUse CA-125 testing only when the policy’s qualifying clinical criteria are met, not for routine screening of average-risk individuals without signs or symptoms.
    SourceLink
    POLICY UPDATE CHANGES

    A Summary for Members and Families section was added during the 08/13/2026 review.

    The description, discussion/general information, references, and websites for additional information sections were revised during the 08/13/2026 review.

    The Coding section was updated for 10/01/2026 ICD-10-CM changes and added codes QA1.790-QA1.791.

    The 08/07/2025 review revised the description, discussion/general information, definitions, references, and websites for additional information sections.

    The 08/08/2024 revision revised criteria for suspected ovarian cancer and repeat testing.

    The 08/08/2024 revision added ICD-10-CM codes Z85.038, Z85.07, Z85.831, Z86.002 and removed C51.8.

    86304Covered procedure code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6Cancer categories in primary criterion
    30Surveillance starting age
    Not coveredAverage-risk screening
    Not specifiedRoutine testing interval
    2Codes added in 2026 update

    Medical Necessity Criteria

    Medically Necessary CA-125 Testing

    Covered when any one of the following indication groups is met:

    Covered indications

    • Initial evaluation or residual tumor assessment

      • Clinical purpose

        • Initial evaluation for suspected or diagnosed disease.
        • Determination of whether residual tumor exists after surgical therapy.
      • Qualifying malignancy

        • Appendiceal adenocarcinoma.
        • Endometrial cancer.
        • Ovarian, primary peritoneal, or fallopian tube cancer.
        • Pancreatic adenocarcinoma.
        • Peritoneal mesothelioma.
        • Uterine neoplasms, including endometrial cancer and uterine sarcoma.
    • Evaluation of a pelvic or abdominal mass when malignancy is suspected.
    • Evaluation of signs or symptoms suggestive of ovarian cancer.
    • Surveillance of ovarian cancer in an individual with hereditary breast and ovarian cancer syndrome.Starting at age 30 years until the individual chooses risk-reducing bilateral salpingo-oophorectomy.
    • Repeat CA-125 testing to monitor response to therapy or assess recurrence when suggested by clinical factors.

    Not Medically Necessary

    Not medically necessary when the covered criteria are not met:

    Not medically necessary: CA-125 testing is not medically necessary when the policy criteria are not met, including routine screening of an average-risk individual without signs or symptoms.

    This includes testing associated with diagnoses not listed in the medically necessary coding section.

    Routine CA-125 screening is not medically necessary for an average-risk individual who has no signs or symptoms of ovarian cancer.

    Routine ovarian cancer screening with CA-125 alone or with transvaginal ultrasound has not been shown to reduce mortality. False-positive results may lead to invasive diagnostic testing, including unnecessary surgery. Concurrent testing may be appropriate only for certain high-risk individuals with a qualifying hereditary cancer syndrome who have not elected risk-reducing removal of the tubes and ovaries.

    CA-125 testing is not medically necessary when the policy’s qualifying clinical criteria are not met. This includes procedure code 86304 when it is submitted with a diagnosis not listed in the medically necessary coding section.

    Covered Clinical Indications

    Initial Evaluation or Residual Tumor Assessment

    Covered when either qualifying clinical purpose is present and one of the listed malignancies applies:

    ALL of the following

    • Clinical purpose

      • Initial evaluation for suspected or diagnosed disease.
      • Determination of whether residual tumor exists after surgical therapy.
    • Qualifying malignancy

      • Appendiceal adenocarcinoma.
      • Endometrial cancer.

    Coding and Covered Services

    When services are Medically NecessarymixedCovered
    86304Immunoassay for tumor antigen, quantitative; CA 125.
    C18.1Malignant neoplasm of appendix.
    C25.0-C25.9Malignant neoplasm of pancreas.
    C45.1Mesothelioma of peritoneum.
    C48.0-C48.8Malignant neoplasm of retroperitoneum and peritoneum.
    C53.0-C55Malignant neoplasm of cervix uteri, corpus uteri, uterus part unspecified.
    C56.1-C56.9Malignant neoplasm of ovary.
    C57.00-C57.9Malignant neoplasm of other and unspecified female genital organs.
    C7B.04Secondary carcinoid tumors of peritoneum.
    C76.2-C76.3Malignant neoplasm of abdomen, pelvis.
    1–10 of 46
    1/5
    When services are Not Medically NecessarymixedNot Covered
    No codes listed
    Codes added in 10/01/2026 ICD-10-CM updateICD-10
    QA1.790Added in the 10/01/2026 ICD-10-CM Coding update; description not provided in this window.
    QA1.791Added in the 10/01/2026 ICD-10-CM Coding update; description not provided in this window.
    Code added in 10/01/2025 ICD-10-CM updateICD-10
    R10.A3Added to the end of an existing code range in the 10/01/2025 ICD-10-CM Coding update; description not provided in this window.
    Codes changed in 08/08/2024 Coding revisionICD-10
    Z85.038Added in the 08/08/2024 Coding revision; description not provided in this window.
    Z85.07Added in the 08/08/2024 Coding revision; description not provided in this window.
    Z85.831Added in the 08/08/2024 Coding revision; description not provided in this window.
    Z86.002Added in the 08/08/2024 Coding revision; description not provided in this window.
    C51.8Removed in the 08/08/2024 Coding revision; description not provided in this window.
    Hereditary Breast and Ovarian Cancer Syndrome Surveillance
    Surveillance periodFor individuals with hereditary breast and ovarian cancer syndrome, ovarian cancer surveillance begins at age 30 years and continues until they choose risk-reducing bilateral salpingo-oophorectomy.

    Provider and Billing Guidance

    Denial Risk

    Avoid testing outside qualifying criteria

    Avoid ordering CA-125 testing for routine screening of an average-risk individual without signs or symptoms; it is not medically necessary and may lead to false-positive results, additional testing, or unnecessary surgery. For CPT 86304, services billed with diagnoses not listed in the medically necessary coding section are also not medically necessary.

    • Use CA-125 only when a qualifying clinical criterion is met, such as suspected malignancy, a pelvic or abdominal mass with suspected malignancy, suggestive ovarian-cancer symptoms, specified hereditary-risk surveillance, or clinically indicated monitoring of treatment response or recurrence.
    • Do not submit CPT 86304 with diagnoses outside the policy’s medically necessary coding section.

    Testing Frequency and Clinical Timing

    CA-125 Testing Frequency
    Routine intervalNo specific routine CA-125 testing interval is established by the cited NCCN guidance.
    When testing may occurTesting may be performed when clinically indicated, including before chemotherapy cycles and after primary therapy in relevant ovarian cancer settings.

    Clinical Background

    CA-125 is a tumor marker commonly expressed by epithelial ovarian neoplasms and by tissues lining the endometrium, fallopian tubes, pleura, peritoneum, and pericardium. CA-125 levels may assist with evaluation of selected malignancies, monitoring treatment response, and assessing recurrence; however, levels may also be elevated in benign conditions such as endometriosis, pregnancy, and pelvic inflammatory disease.

    Definitions

    Ascites
    DefinitionThe accumulation of fluid in spaces within the abdomen.
    Biomarker
    DefinitionA measurable indicator of a biological state or condition obtained from bodily fluids, such as blood or urine, or tissue samples. Biomarkers are used to diagnose diseases, monitor disease progression, predict disease prognosis, and track treatment response.
    Carcinoembryonic Antigen (CEA)
    DefinitionA glycoprotein molecule associated with specific forms of cancer, particularly colorectal cancer. CEA may be used as a biomarker in diagnostic and prognostic evaluations.
    Progression

    Non-Covered Uses

    The policy does not cover routine CA-125 screening for average-risk asymptomatic individuals. Testing is also not covered when the policy’s qualifying clinical criteria are not met, including when procedure code 86304 is associated with a diagnosis not listed in the medically necessary coding section.

    Policy Summary
    PayerAnthem
    PolicyCancer Antigen 125 Testing
    Policy CodePolicy CG-LAB-32
    Change TypeModified
    Effective DateOctober 1, 2026
    Last ReviewAug 13, 2026
    Next Review DateNot specified
    Key ActionUse CA-125 testing only when the policy’s qualifying clinical criteria are met, not for routine screening of average-risk individuals without signs or symptoms.
    SourceLink
    On This Page
    Medical Necessity CriteriaCovered Clinical IndicationsCoding and Covered ServicesProvider and Billing GuidanceTesting Frequency and Clinical TimingClinical BackgroundDefinitionsNon-Covered Uses
  1. Ovarian, primary peritoneal, or fallopian tube cancer.
  2. Pancreatic adenocarcinoma.
  3. Peritoneal mesothelioma.
  4. Uterine neoplasms, including endometrial cancer and uterine sarcoma.
  5. Pelvic or Abdominal Mass or Ovarian Cancer Symptoms

    Covered for either of the following qualifying clinical indications:

    Qualifying indication

    • Evaluation of a pelvic or abdominal mass when malignancy is suspected.
    • Evaluation of signs or symptoms suggestive of ovarian cancer.

      Examples include ascites, abdominal distension or bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, and urinary urgency or frequency when not linked to another definitive source of malignancy.

    Hereditary Breast and Ovarian Cancer Syndrome Surveillance

    Covered for ovarian cancer surveillance when both of the following conditions are met:

    ALL of the following

    • The individual has hereditary breast and ovarian cancer syndrome and is undergoing surveillance for ovarian cancer.
    • Surveillance begins at age 30 years and continues until the individual chooses risk-reducing bilateral salpingo-oophorectomy.Age 30 years until risk-reducing bilateral salpingo-oophorectomy

    Repeat Testing for Treatment Response or Recurrence

    Repeat testing is covered when either of the following purposes applies and clinical factors support testing:

    ALL of the following

    • Clinical purpose

      • Monitor response to therapy.
      • Assess for recurrence when suggested by clinical factors.
    • Relevant clinical context

      • For ovarian cancer, monitoring may be clinically indicated before each cycle of chemotherapy.
      • For ovarian cancer, monitoring may be clinically indicated after completion of primary therapy, including when CA-125 was initially elevated.
      • Testing for recurrent ovarian cancer may be appropriate with a rising CA-125 when there was no previous chemotherapy, with a serially rising CA-125 after previous chemotherapy, or for platinum-sensitive disease when CA-125 is rising without radiographic evidence of disease.
    DefinitionDisease that worsens or spreads without ever having gone away.
    Recurrence
    DefinitionCancer that has returned after treatment, often undetected for a certain period of time. Recurrence can happen at the same location as the initial tumor or at a different site in the body.
    Screening Test
    DefinitionA test administered to individuals when there are no signs or symptoms of a specific condition.
    Surveillance
    DefinitionTesting or monitoring used to detect early signs of recurrence in diseases, particularly cancer, or to monitor individuals at increased risk of a disease.
    Uterine Neoplasm
    DefinitionA type of cancer that forms in the tissues of the uterus. Uterine cancer includes endometrial cancer, which begins in the cells lining the uterus, and uterine sarcoma, which begins in the muscle or other tissues in the uterus.
    Uterine Neoplasm
    DefinitionA cancer arising in uterine tissues, including endometrial cancer and uterine sarcoma.